Prospective Clinical and Biologic Study of Secondary Cutaneous Effects in Targeted Cancer Therapies (SKINTARGET)
August 17, 2026 updated by: Gustave Roussy, Cancer Campus, Grand Paris
The aim of the study is to do a descriptive analysis of the cutaneous toxicity observed in patients treated using targeted therapies in order to have a better understanding of the skin pathophysiology.
Study Overview
Study Type
Interventional
Enrollment (Actual)
141
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Val de Marne
-
Villejuif, Val de Marne, France, 94805
- Gustave Roussy Cancer Campus Grand Paris
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients with cancer beginning a targeted therapy
- Patients able to follow the protocol
- Age >/= 18 years old
- Signed inform consent
Exclusion Criteria:
- Patient unable to follow the protocol, having a non cooperative behavior or unable to come to follow up visits or unable to complete the study
- Pregnant or breastfeeding woman
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Patients having received targeted therapies
Patients treated using targeted therapies
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of clinical secondary effects bind to targeted therapies
Time Frame: Every 28 days up to 5 years
|
Dermatological exam including questionnaire, clinical examination and photographies
|
Every 28 days up to 5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Chair: Caroline Robert, MD, Gustave Roussy, Cancer Campus, Grand Paris
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 12, 2011
Primary Completion (Actual)
June 22, 2022
Study Completion (Actual)
June 22, 2022
Study Registration Dates
First Submitted
February 7, 2014
First Submitted That Met QC Criteria
August 3, 2015
First Posted (Estimated)
August 7, 2015
Study Record Updates
Last Update Posted (Actual)
August 19, 2026
Last Update Submitted That Met QC Criteria
August 17, 2026
Last Verified
August 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2010-A01052-37
- 2010/1664 (Other Identifier: CSET number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.